Market Trends of Inflammatory Bowel Disease (IBD) Therapeutics Industry
The JAK inhibitors Segment is Expected to Hold a Significant Market Share in the Inflammatory Bowel Disease (IBD) Therapeutics Market.
The Janus Kinase (JAK) inhibitors are a major fraction of the drug classes used in the treatment of IBD. For instance, according to an article published by Drugs in March 2023, Janus kinase (JAK) inhibitors are widely used for the treatment of IBD. The source also stated that JAKs such as tofacitinib, a non-selective small molecule JAK inhibitor, and upadacitinib and filgotinib, which are selective JAK-1 inhibitors, have been approved by the United States Food and Drug Administration (FDA) for moderate-to-severe active ulcerative colitis. Thus, the usage of JAK inhibitors in treating IBD is expected to boost segment growth.
Recently, combination therapies have been studied as a crucial resource for the treatment of refractory IBD. For instance, as discussed in an article published by Gastroenterology & Hepatology in January 2023, JAK inhibitors, in combination with other biological treatment methods, have illustrated an adequate safety profile and comparatively good efficacy in the treatment of IBD.
Significant discoveries in the treatment of IBD, especially the use of biologics, are expected to increase the Inflammatory Bowel Disease (IBD) Therapeutics market. JAK inhibitors, often known as oral biologics, are antibodies that are synthesized in vivo that act specifically by stopping certain inflammation-causing proteins. There is a large importance placed on the research of using JAK inhibitors and the magnitude of the research work being done on further combination therapy is substantial. These factors are expected to have a significant impact on the growth of the IBD treatment market in the upcoming period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period.
North America is expected to experience growth during the forecast period of the study due to factors such as the rising prevalence of IBD, the strong foothold of key market players in the country, and the rising research and development activities by pharmaceutical and biopharmaceutical companies for the development of IBD therapeutics. According to the data published by Crohn's and Colitis Canada and Pfizer Canada in November 2022, it was estimated that over 300,000 Canadians were believed to be living with IBD in 2022. By 2030, that number is expected to rise to 403,000 (1 in 100 people). Thus, the high burden of IBD in Canada is expected to boost market growth.
Furthermore, according to an article updated by NCBI in June 2022, North American incidence of inflammatory bowel disease (IBD) ranges from 2.2 to 19.2 cases per 100,000 person-years for ulcerative colitis and 3.1 to 20.2 cases per 200,000 person-years for CD. Thus, the high prevalence of IBD is expected to boost the demand for therapeutics for IBD during the forecast period. Hence, the abovementioned factors, such as the rising prevalence of IBD, are expected to enhance the market growth in the region over the forecast period.
